Zhejiang Shouxiangu Pharmaceutical Co Ltd
SSE:603896
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zhejiang Shouxiangu Pharmaceutical Co Ltd
Income from Continuing Operations
Zhejiang Shouxiangu Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zhejiang Shouxiangu Pharmaceutical Co Ltd
SSE:603896
|
Income from Continuing Operations
¥132.4m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Hengan International Group Company Ltd
HKEX:1044
|
Income from Continuing Operations
¥2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Proya Cosmetics Co Ltd
SSE:603605
|
Income from Continuing Operations
¥1.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
By-health Co Ltd
SZSE:300146
|
Income from Continuing Operations
¥816.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
3%
|
|
|
S
|
Shanghai Chicmax Cosmetic Co Ltd
HKEX:2145
|
Income from Continuing Operations
¥1.2B
|
CAGR 3-Years
103%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
G
|
Giant Biogene Holding Co Ltd
HKEX:2367
|
Income from Continuing Operations
¥1.9B
|
CAGR 3-Years
24%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Zhejiang Shouxiangu Pharmaceutical Co Ltd
Glance View
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the breeding, cultivation, processing, and sale of Chinese herbal pieces and health food. The company is headquartered in Jinhua, Zhejiang and currently employs 1,026 full-time employees. The company went IPO on 2017-05-10. The firm's main products include ganoderma lucidum spore powder, Tiepi Fengdou granule, ganoderma extract products and fresh dendrobium officinales, among others. The firm mainly operates its businesses in domestic markets through wholesaling and direct sales.
See Also
What is Zhejiang Shouxiangu Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
132.4m
CNY
Based on the financial report for Sep 30, 2025, Zhejiang Shouxiangu Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 132.4m CNY.
What is Zhejiang Shouxiangu Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
0%
Over the last year, the Income from Continuing Operations growth was -43%. The average annual Income from Continuing Operations growth rates for Zhejiang Shouxiangu Pharmaceutical Co Ltd have been -18% over the past three years .
